By Jason Napodano, CFA
We have reviewed twenty scientific papers in an attempt to better understand the mechanism of action, preclinical data, and the commercial potential for Amarantus Biosciences' (OTCQB:AMBS) Mesencephalic Astrocyte-Derived Neurotrophic Factor (OTCPK:MANF). Below is a review of those papers, in chronological order from the date they were first published.
Paper # 1 - Petrova PS, Raibekas A, Pevsner J, Vigo N, Anafi M, Moore MK, Peaire AE, Shridhar V, Smith DI, Kelly J, Durocher Y, Commissiong JW. (April 2003) MANF: A New Mesencephalic, Astrocyte-Derived Neurotrophic Factor with Selectivity for Dopaminergic Neurons. Journal of Molecular Neuroscience, Vol.20/2:173-187.
The Petrova et al. paper above was the first characterization we found on MANF. Petrova...
Only subscribers can access this article, which is part of the PRO research library covering 3,760 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: